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Abstract: Background: Naloxegol antagonizes peripheral opioid-related side effects without preventing opioid-related analgesia. However, the effect of naloxegol on opioid-induced bladder dysfunction
remains unknown. Hypothesis: patients given naloxegol have lower residual bladder urine volume
than those given placebo. Methods: 136 patients scheduled for elective hip and knee surgery were
randomized to oral naloxegol or placebo given the morning of surgery, and on the first two postoperative mornings. Residual urine volume was measured ultrasonographically within 30 min after
voiding once in the morning and once in the afternoon for two postoperative days. Opioid-related
Symptom Distress Scale (ORSDS), the need for indwelling urinary catheterization, and quality of
recovery (QoR) score were secondary outcomes. Results: 67 were randomized to naloxegol and 64 to
placebo. We did not identify a significant effect on urine residual volume, with an estimated ratio of
geometric means of 0.9 (0.3, 2.6), p = 0.84. There were no significant differences in ORSDS or QoR.
There were 19 (29%) patients assigned to naloxegol who needed indwelling urination catheterization
versus 7 (11%) patients in the placebo group, p = 0.012. Conclusions: Our results do not support use
of naloxegol for postoperative urinary retention after hip and knee surgery.

10.3390/jcm11020454
Academic Editor: Tomoyuki

Keywords: anesthesia; urinary retention; naloxegol; residual bladder urine volume

Kawamata
Received: 10 November 2021
Accepted: 13 January 2022

1. Introduction

Published: 17 January 2022

Post-operative urinary retention is a common postoperative complication, with an
overall prevalence ranging from 2.1% to 70% depending on how the syndrome is defined
and evaluated [1,2]. Post-operative urinary retention can cause long-term bladder dysfunction, chronic kidney disease, urinary tract infections, and even sepsis—consequently
delaying hospital discharge and increasing hospital costs [1–4]. The risk of urinary retention is enhanced by certain types of surgery, advanced age, neuraxial blocks, and certain
medications [1–4].
Post-operative opioids are an established cause of post-operative urinary retention [5,6].
Consistent with this mechanism, naloxone frequently ameliorates urinary retention [7].
However, naloxone also antagonizes analgesia which limits its clinical utility. Naloxegol is
a naloxone analog with limited blood brain barrier permeability [8]. The drug therefore
antagonizes peripheral opioid receptors and opioid-related side effects without preventing
opioid-related analgesia which is centrally mediated [8]. The drug was approved by the US
Food and Drug Administration in 2014 for opioid-induced constipation, [9] but whether
naloxegol similarly reduces opioid-induced bladder dysfunction remains unknown.
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The goal of this trial was to evaluate the effect of naloxegol on postoperative opioidinduced bladder dysfunction. Specifically, we tested the primary hypothesis that patients
randomized to naloxegol (versus placebo) the morning of surgery and once each morning
for each of the first two postoperative days have lower residual bladder urine volume.
Secondarily, we compared naloxegol with placebo on opioid-related side effects, the need
for indwelling urinary catheterization, and the quality of recovery.
2. Methods
Our investigator-initiated, double-blind, randomized trial was approved by the institutional review board of Cleveland Clinic. Consenting patients scheduled for elective hip
and knee surgeries were enrolled with IRB approval (Number 17-765, 3 July 2017). The
trial was registered at ClinicalTrials.gov (accessed on 9 November 2021) before the first
patient was enrolled (NCT 03235739). There were no substantive changes to the protocol
after initiation of patient enrollment. Our study was a priori defined as a pilot trial.
The trial enrolled non-pregnant adults scheduled for elective hip and knee surgery who
were expected to have substantial postoperative pain requiring administration of opioids.
Patients were excluded if they: (1) had hepatic disease (liver enzyme concentrations twice
normal); (2) had kidney disease (serum creatinine > 2.0); (3) had history of bladder cancer;
(4) were scheduled for perioperative nerve blocks; (5) took anticholinergic medications
or had conditions or comorbidity causing urinary retention; (6) were expected to require
an indwelling urinary catheter before or immediately after surgery due to immobility;
(7) had pre-existing urinary tract infections or other urogenital comorbidity (incontinence,
cysto-ureteric reflux, known bladder retention) or conditions which can cause urinary retention; (8) had severe peptic ulcer disease, diverticular disease, infiltrative gastrointestinal
tract malignancies, or peritoneal metastases; (9) were known or suspected of having a
disrupted blood brain barrier, including Alzheimer’s disease, stroke, poliomyelitis, cerebral
palsy, multiple sclerosis, spinal lesions, and Parkinson’s disease; (10) had gastrointestinal
obstruction or perforation; (11) were taking strong CYP3A4 inhibitors (some antibiotics,
antifungals, protease inhibitors, and antidepressants) or strong CYP3A4 inducers, other
opioid antagonists; or, (12) reported hypersensitivity to naloxegol or any of its metabolites.
2.1. Protocol
Patients were randomized 1:1 to oral naloxegol 25 mg (maximum allowed daily dose)
or identical-appearing placebo, stratified on chronic opioid use. Study drug was provided
by the research pharmacy. Therefore all investigators and clinicians were fully blinded.
Chronic opioid use was defined as more than 30 consecutive days within three preoperative
months, at a daily dose of 15 mg or more of morphine or equivalent. The trial drug was
prepared by our research pharmacy; investigators, clinicians, and patients were thus fully
blinded to treatment. It was given orally the morning of surgery, and on the first two
postoperative mornings.
General anesthesia was induced and maintained per routine, usually with propofol
and the volatile anesthetic sevoflurane. Intraoperative analgesia was restricted to shortacting opioids, usually fentanyl (boluses of 25–50 µg as needed). Spinal anesthesia was
done with isobaric bupivacaine (10–15 mg). Indwelling urinary catheters were inserted in
patients with an expected surgical duration exceeding 3 h, and in those in whom meticulous
fluid status monitoring was desired. Intraoperative and postoperative fluid management
was entirely at the discretion of the responsible clinicians.
In the post-anesthesia care unit and throughout the postoperative period, patients
were managed at the discretion of the surgical team and the staff anesthesiologist. Intermittent urinary catheterization was used in postanesthesia care unit and/or surgical
ward when medically indicated, generally when bladder volume was believed to exceed
400 mL. Patients were given intravenous boluses of fentanyl 25–50 µg or hydromorphone
(0.2–0.4 mg) as needed at 10-min intervals in the post-anesthesia recovery unit to target
pain scores at rest < 4 on a 0–10 verbal response scale.
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Clinicians managing postoperative pain on surgical wards were blinded to aims of the
study and adjusted opioid analgesia (intravenous boluses of hydromorphone (0.2–0.4 mg)
or fentanyl (25–50 µg)) as necessary to target pain scores at rest <4 on a 0–10 verbal response
scale throughout hospitalization. When patients were able to tolerate oral intake, they were
transitioned to oral opioids (hydromorphone, oxycodone) per clinical routine.
2.2. Measurements
Demographic and baseline characteristics were retrieved from electronic medical
records for patients. Trial data were stored in a custom Redcap database.
The primary outcome, residual urine volume, was measured within 30 min after
voiding using a battery-powered, portable ultrasound bladder scan BVI 3000 (Verathon,
Bothell, WA, USA). The device provides three-dimensional images of the bladder and uses
automated technology to estimate bladder volume. Portable bladder ultrasound devices
are accurate, reliable, cost-effective, and noninvasive. Bladder ultrasound estimates of
residual volume are as accurate as catheterization with no meaningful effects of age, sex, or
body mass index [10,11].
The ultrasonic bladder scanner was positioned on the suprapubic area and held
stationary during measurement scanning. The diameter of the bladder and volume of urine
was calculated from the scan data. Scans were repeated three times and the results averaged.
Bladder scans were performed by trained physician investigators once in the morning and
once in the afternoon on postoperative days 1 and 2, for a total of four measurements per
patient. The surgical team was blinded to volume determined by scanning. Presence of
indwelling bladder catheters was recorded.
Secondary outcomes included opioid-related side effects, the need for indwelling
urinary catheterization, and quality of recovery (QoR) score. Opioid-related Symptom
Distress Scale (ORSDS) is a 4 point-scale that evaluates three symptom distress dimensions
(frequency, severity, bothersomeness) for opioid-related side effects [12]. The 12 elements
of the ORSDS are nausea, vomiting, constipation, difficulty passing urine, difficulty concentrating, drowsiness, lightheaded, fatigue, feeling confused, itchiness, dry mouth, and
headache [12]. The ORSDS questionnaire was administered by a trained investigator on
first and second postoperative days while patients remained hospitalized.
Quality of recovery is a validated scoring system that quantifies patients’ early postoperative health status with range of 0–150 [13]. We used the 15-question version, the
QoR-15, [13] on the second postoperative day or the day of discharge if earlier. The minimal
clinically important difference was accepted as 8.0 [14].
There were also two a priori exploratory outcomes: (1) satisfaction with the quality of
recovery, as measured on a subjective 100-point scale (where 0 means not satisfied at all
and 100 means completely satisfied); and, (2) length of hospital stay after surgery.
2.3. Statistical Analysis
The statistical analysis plan was developed before patient enrollment and was included
in our IRB application. Analyses were modified intent-to-treat and included all randomized
patients who received some study drug. Demographic and baseline characteristics were
summarized using appropriate statistics (i.e., means ± standard deviations, medians
[Q1, Q3], orq
N (%)). Baseline variables with absolute standardized differences (ASD) > 0.34

(i.e., 1.96 × n1 + n12 ) were considered as imbalanced [15] and adjusted for in all primary
1
and secondary analyses. We used an overall alpha of 0.05 for both primary and secondary
analyses, with a significance criterion of 0.05 for the primary analysis and 0.017 for each
secondary analysis (i.e., 0.05/3, Bonferroni correction).
For the primary analysis, urine residual was to be log-transformed if it did not meet
normality assumption. We used a linear mixed effects model adjusting for within-subject
correlation (using a first order autoregressive correlation structure) across the four time
points, where the random effects were subject and fixed effects were time, treatment, and
chronic opioid use. First, we tested the group-by-time interaction to assess whether the
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treatment effect differed over time (the significance level of interaction was 0.20). If it
appeared to differ, we would report the treatment effect separately for each measurement
time using a Bonferroni correction. Absent an interaction, we would assess the group
difference on the volume of residual urine collapsing over time. We would also test if
there was different treatment effect among chronic opioid users and nonusers by adding
an interaction term with treatment.
We used multiple imputation for longitudinal data to impute missing values of the
repeated measurements of the primary outcome. Fully conditional specification (FCS)
method was used to impute missing values. Then the 10 imputed complete datasets were
analyzed to obtain the pooled results. This imputation was completed using MI (multiple
imputation) procedure in SAS. The results of analysis using complete cases are reported
as a sensitivity analysis. Because the log-transformed primary outcome was not normally
distributed, we did another sensitivity analysis using Wilcoxon rank sum test to compare
groups over 4 time periods by pooling all the measurements in each group.
For the secondary analysis, we assessed the treatment effect on ORSDS by fitting
a linear mixed model assuming an autoregressive correlation structure. The effect of
naloxegol on the incidence of the need of indwelling urinary catheterization was assessed
using Pearson chi-square test. The QoR score was compared between treatment and control
group with a Wilcoxon rank sum test. Pain management satisfaction scores and duration of
hospitalization were summarized for exploratory analysis.
2.4. Sample Size
Our sample size estimate was based on the linear mixed effects model for repeated
measured data to test the primary hypothesis that patients who received Naloxegol 25 mg
given once in the morning every day would have lower mean volume of residual urine in
bladder when compared to placebo. Sixty-two patients per group were needed to have 90%
power at a two-sided alpha level of 0.05 to detect a difference of 24 mL with an assumed
standard deviation of 60, which is equivalent to a mean ratio of 0.80 if the mean of control
group is assumed to be 125. To be conservative we assumed four measurements per patient
with a correlation of 0.3. Assuming 10% loss to follow-up, we needed 12 more patients to
reach the planned power with an end-sample size of 136. In addition to the 136 patients, we
enrolled two pilot patients whose data were not considered for analysis to test feasibility of
recruitment, protocol adherence, randomization process, and data collection. Data quality
was confirmed at 33% enrollment.
3. Results
A total of 136 patients were enrolled, although five patients withdrew and were
excluded from the analysis (Figure 1). Among the remaining 131 patients, 67 were randomized to naloxegol and 64 to placebo. Baseline and demographic characteristics are
summarized in Table 1. All patients had hip and knee surgery. There were some imbalances
observed in baseline characteristics. But since our trial was randomized, imbalance should
reflect chance imbalances rather than confounding; therefore, no adjustment was made
during primary and secondary analyses.
Post-operative urinary retention independent of group allocation was (median (Q1, Q3))
102 (7, 209) mL in the morning of postoperative day 1, 34(0, 206) mL in the evening of
postoperative day 1, 29 (0, 144) mL the morning of postoperative day 2, and 13 (0, 76) mL
the evening of postoperative day 2.
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Table
Table 1.
1. Baseline
Baseline characteristics
characteristics by
by group.
group.

Factor
Factor
Demographic
Demographic
Age (yrs.)
Age (yrs.)
Female
Female
3
3
RaceRace
Caucasian
Caucasian
African
American
African
American
Other
Other
2) 2
BMI (kg/m
BMI (kg/m
)
ASAASA
status
status
1 1
2 2
3
3
4
4
Apfel PONV score
Apfel
PONV
score
Chronic opioids use
Chronictype
opioids use
Surgery
Surgery
type
Hip
KneeHip
Surgery duration,
Kneehour
Medical
SurgeryHistory
duration, hour
Kidney
Disease
Medical
History
Chronic Pulmonary
Disease
Kidney Disease
Obstructive Sleep Apnea
Chronic Pulmonary Disease
Diabetes Mellitus
Obstructive
Sleep Apnea
Myocardial
Infarction
Diabetes
Mellitus
Ischemic Heart Disease
Myocardial
Infarction
Neurologic Diseases
Ischemic
Heart Disease
Chronic Pain
Neurologic Diseases

NaloxegolNaloxegol
(n = 67) (n = 67)

Placebo (nPlacebo
= 64) (n = 64)

64 ± 13
32 (48)

64 ± 13
32 (48)

62 ± 11
32 (50)

62 ± 11
32 (50)

59 (89)
6 (9)
1 (2)
29 ± 6

59 (89)
6 (9)
1 (2)
29 ± 6

57 (92)
5 (8)
0 (0)
30 ± 7

57 (92)
5 (8)
0 (0)
30 ± 7

1 (2)
1 (2)
8 (12)
8 (12)
52 (77)
52 (77)
6 (9)
6 (9)
2.0 (2.0, 3.0)
2.0
(2.0,
3.0)
36 (13)
36 (13)
67 (100)
67 (100)
0 (0)
3.6 (2.9, 4.7) 0 (0)
3.6 (2.9, 4.7)
4 (6)
9 (13)
4 (6)
9 (13)
9 (13)
7 (10)
9 (13)
6 (9)
7 (10)
14 (21)
6 (9)
7 (10)
14 (21)
1 (2)
7 (10)

1 (2)
1 (2)
15 (23) 15 (23)
46 (72)
46 (72)
2 (3)
2 (3)
1
2.0 (2.0, 3.0)
2.0
(2.0,
3.0) 1
32 (13)
32 (13)
64 (100)
64 (100)
0 (0)
3.5 (2.9, 4.5) 1 0 (0)
3.5 (2.9, 4.5) 1
1 (2)
9 (14)
1 (2)
6 (10)
9 (14)
7 (11)
6 (10)
4 (6)
7 (11)
10 (16)
4 (6)
12 (19)
10 (16)
5 (8)
12 (19)

ASDASD

0.177
0.177
0.0460.046
0.1800.180

0.0590.059
0.3740.374

0.138
0.03 0.138
0 0.03
0
0.062
0.062
0.231
0.0180.231
0.123
0.018
0.021
0.0980.123
0.1300.021
0.2440.098
0.3080.130
0.244
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Table 1. Cont.
Factor

Naloxegol (n = 67)

Placebo (n = 64)

ASD

Current Smoker
Drug User
Alcohol Abuse
Cancer
Anesthesia type 1
General anesthesia
Spinal anesthesia
Intraoperative variables
Colloids, ml
Crystalloids, ml
RBC, cc
Platelets, cc
Urine, cc
Intraoperative opioid use

9 (13)
2 (3)
10 (15)
10 (15)

7 (11)
5 (8)
7 (11)
6 (10)

0.071
0.219
0.254
0.165
0.21

46 (69)
21 (31)

45 (71)
18 (29)

0 (0, 500)
2000 (1400, 2700)
0 (0, 0)
0 (0, 0)
0 (0, 420)
20 (5.0, 30.3)

0 (0, 250) 1
1800 (1400, 2700) 1
0 (0, 0) 1
0 (0, 0) 1
0 (0, 460) 1
20 (7.5, 25.3) 1

0.101
0.051
0.336
0.173
0.081
0.01

BMI: body mass index; ASA: American Society of Anesthesiologists; PONV: Postoperative nausea and vomiting.
Statistics presented as means ± SDs, medians (Q1, Q3), or N (column %). ASD: absolute standard difference;
standardized difference is the difference in means or proportions divided by the pooled standard deviation. ASD
larger than 0.34 was considered as imbalanced. Superscripts of summary statistics represent missing number.

3.1. Primary Analyses
The median (Q1, Q3) of urine residual volume was 62 (5, 187) in patients given
naloxegol and 114 (13, 247) in those given placebo from day 1 morning to 0 (0, 122)
(treatment) and 28 (0, 66) (control) at day 2 afternoon. After log transformation, urine
residual volumes were more normally distributed. The treatment-by-time interaction was
not significant (p = 0.77). We did not find significant treatment effect on urine residual
volume, with an estimated ratio of geometric means of 0.90 (0.32, 2.55), p = 0.84.
The treatment effect did not differ between chronic opioid users and non-users (interaction p = 0.92). According to the complete case analysis, naloxegol did not significantly affect
the mean urine residual volume compared to placebo over postoperative day 1–2, with
estimated ratio of geometric means of 0.82 (0.26, 2.56), p = 0.73 (Table 2 and Figures 2 and 3).
The treatment effect also did not differ across time or across chronic opioid user groups in
the complete case analysis.
Table 2. Treatment effect on urine residual.
Postoperative Day
Urine residual
volume (mL)

Total (n = 114) b

Naloxegol
(n = 59) a,b

Placebo
(n = 55) a,b

Overall
Day 1 AM
Day 1 PM
Day 2 AM
Day 2 PM

102 (7, 209)
34 (0, 206)
29 (0, 144)
13 (0, 76)

62 (5, 187)
48 (0, 206)
32 (0, 152)
0 (0, 122)

Ratio of Geometric
Means (95% CI) c

p-Value

0.90 (0.32, 2.55)

0.84

114 (13, 247)
31 (0, 169)
28 (0, 122)
28 (0, 66)

CI: confidence interval. a : The primary analysis included 114 patients due to complete missing of 17 patients (nine
in control group and eight in treatment group). b : Summary statistics of primary outcome urine residual was
reported as median (Q1, Q3) during the first two postoperative days. c : The ratio of geometric means (Naloxegol
versus placebo) was estimated using a linear mixed-effect model with repeated measures assuming a first order
auto-regressive correlation structure (known as AR(1)) after multiple imputation for missing data. The random
effect was subject and the fixed effects included time, treatment, and chronic opioid use. The treatment effect did
not differ across time (p = 0.77) or across chronic opioid use (p = 0.92).
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3.2. Secondary Analyses
The median (Q1, Q3) of opioid-related side effects (ORSDS) score at postoperative day 2 was 0.34 (0.2, 0.64) for treatment and 0.34 (0.13, 0.62) for control (Table 3,
Supplementary Material Tables S1 and S2). There were 19 (29%) patients assigned to naloxegol who needed indwelling urination catheterization versus seven (11%) patients in the
placebo group. Treated patients had borderline higher risk of needing an indwelling
catheterization, with an estimated relative risk (98.3% CI) of 2.6 (0.98, 6.8), p = 0.012 from
Pearson chi-square (Table 3, Supplementary Material Tables S1 and S2) (p = 0.022 from
continuity adjusted chi-square). There were also no significant differences in opioid-related
side effects or quality of recovery.
Table 3. Treatment effect on secondary outcomes.
Postoperative Day
ORSDS b

N Missing

Naloxegol (n = 67)

Placebo (n = 64)

Overall
Day 1
Day 2

3
24

0.53 (0.34, 0.79)
0.34 (0.2, 0.64)

0.45 (0.31, 0.81)
0.34 (0.13, 0.62)

Indwelling need b

Until discharge

4

19 (0.3)

7 (0.1)

QoR-15 Score b

Discharge day

9

119 (103, 131)

123 (115, 133)

Effect Estimate (98.3% CI)

p-Value a

Ratio of geometric means
1.02 (0.63, 1.67)

0.91

Relative risk
2.58 (0.98, 6.80)
Median difference
−5 (−12, 2)

0.012
0.08

ORSDS: opioid-related side effects; QoR: quality of recovery. ORSDS is a 4-point scale score, where the higher
represents more opioid-related side effects. Qor15 score ranges from 0-150, where the higher score represents better
recovery. a : Bonferroni correction was made due to multiple testing (p = 0.017 i.e., p = 0.05/3). b : The treatment
effect on ORSDS was estimated using a mixed effects model assuming auto-regressive correlation structure and
the outcome was log-transformed. Pearson chi-square test was used to test the effect on the indwelling urine
catheterization use. Hodges–Lehmann estimation was used on QoR-15 scores due to non-normality.

3.3. Exploratory Analyses
The median (Q1, Q3) of pain management satisfaction at discharge was 90 (80, 100)
for patients given naloxegol and 90 (83, 100) for patients given placebo. Patients given
naloxegol stayed in the hospital for a median (Q1, Q3) of 3.2 (2.3, 4.3) days, and those
assigned to placebo stayed 2.4 (2.2, 3.3) days. The median (Q1, Q3) of postoperative opioid
use in morphine equivalent was 45 (25, 83) mg for the naloxegol group and 43 (23, 81) mg
for the placebo group.
4. Discussion
Current care approaches including early mobilization and goal-directed fluid management, may reduce postoperative urinary retention. On the other hand, urinary retention is
promoted by spinal anesthesia, advanced age, male sex, large intraoperative fluid volumes
and opioids [2–4,16]. We found that urinary retention was common after hip and knee
surgery and that residual urine volumes were high, especially on the first operative day. It
is possible that high volumes are consequent to enhanced recovery protocols which discourage intraoperative bladder catheterization, and promote removing necessary catheters
at the end of surgery.
Naloxegol did not significantly reduce mean urine residual volume. However, our
pilot trial had limited power; consequently, confidence intervals around the difference were
wide, ranging from a 74% reduction to a 2.4-fold increase in geometric means. Thus, while
our results are not encouraging, we cannot conclude with any certainty that naloxegol has
no clinically meaningful benefit on urinary retention. We used the highest dose of naloxegol
approved for opioid-induced bowel dysfunction [17]. It remains possible that higher doses
are needed to prevent urinary retention. Interestingly, another peripheral opioid antagonist
methylnaltrexone was effective in nonsurgical volunteers in reversal of urinary retention
supporting the theory that peripheral mechanisms play a role in opioid-induced urinary
retention [18].
Curiously, patients randomized to naloxegol were about twice as likely to require
indwelling postoperative bladder catheters. However, the number of events was small and
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our trial was not even remotely powered for this dichotomous outcome. Given the lack of
a causative mechanism, the observation is probably spurious.
Most opioid-related side effects are centrally mediated. For example, 9 of the 12 consequences
evaluated by the ORSDS are completely or mostly centrally mediated. It is therefore unsurprising that naloxegol—which has limited central activity—had no apparent effect on
ORSDS scores. Quality of recovery would be impaired by ileus, but constipation, while
common after major abdominal surgery, is relatively rare in patients who have hip surgery.
It is therefore unsurprising that naloxegol did not reduce opioid-related side effects or
quality of recovery. Since naloxegol is peripherally restricted, the drug does not prevent
opioid-induced analgesia [8]. As might therefore be expected, opioid use and pain scores
were similar in each group.
The most obvious limitation of our trial is restricted power even for our primary
outcome due to a larger observed standard deviation for the primary outcome (SD = 150)
than used in sample size estimate (SD = 60), and fewer secondary outcomes than expected.
Only 15% of randomized patients required postoperative bladder catheterization which
further reduced power. An additional limitation is that our protocol was pragmatic and
did not restrict intraoperative fluids, choice of general or spinal anesthesia, or use of other
drugs, some of which could have contributed to postoperative urinary retention. Our pilot
trial was nonetheless successful in providing good estimates of the variance and incidence
of our outcomes that will guide future trials.
5. Conclusions
Residual urine volumes were similar in patients randomized to 25 mg oral naloxegol
or placebo over the initial 2 days after hip and knee surgery, although confidence intervals
were wide. It thus seems likely that postoperative urinary retention is largely driven
by factors other than postoperative opioids. Furthermore opioid-related side effects and
quality of recovery were similar in the naloxegol and placebo groups. Our results, although
statistically weak, do not support use of naloxegol for postoperative urinary retention after
hip and knee surgery.
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